ArticleMolecular neurodegeneration2026
Parkinson's disease LRRK2 mutations dysregulate iron homeostasis and promote oxidative stress and ferroptosis in human neurons and astrocytes.
Article in Molecular neurodegeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
backgroundIron accumulation is a hallmark of sporadic and familial Parkinson's disease (PD) and correlates with clinical motor symptom severity. The biochemical mechanisms driving iron dyshomeostasis in PD brain and whether these are early or late events in the neurodegenerative process remain unknown. Nigral iron levels in LRRK2-PD patients have been reported to be even higher than in idiopathic PD, and greater in non-manifesting LRRK2 carriers than controls, suggesting that iron accumulation precedes clinical onset in LRRK2-associated PD. However, the cells affected and mechanisms governing iron dyshomeostasis in PD remain unclear.
methodsHere, we investigated multiple independent measures of iron homeostasis in human iPSCs and iPSC-derived models, including glutamatergic and dopaminergic neurons, and astrocytes, carrying pathogenic LRRK2 mutations. High-content and super-resolution microscopy of iron-specific probes and ICP-MS were used to determine iron content and distribution across different cell types and LRRK2 genotypes. Upstream effectors and downstream consequences of iron dyshomeostasis, including oxidative stress and ferroptosis-related phenotypes were also examined.
resultsPathogenic heterozygous LRRK2 mutations were associated with altered iron homeostasis across multiple human cell models. Lysosomal ferrous iron was consistently elevated across iPSC-derived glutamatergic neurons, dopaminergic neurons, and astrocytes carrying LRRK2 mutations and these phenotypes were reduced by varying degrees following treatment with the selective LRRK2 inhibitor, MLi-2. Importantly, we show that lipid peroxidation and ROS levels are elevated in isogenic LRRK2 mutant neurons, while iron chelation or MLi-2 reduced LRRK2-dependent ROS damage. In addition, CRISPR/Cas9-mediated loss of Rab8a produced overlapping iron-related phenotypes, while exogenous Rab8a expression normalized lysosomal iron levels in R1441C LRRK2 iPSCs, supporting a contributory role for Rab8a-dependent trafficking in these effects.
conclusionsTogether, our findings show that pathogenic LRRK2 mutations converge on disrupted iron homeostasis across multiple human neural cell types, including dopaminergic neurons, and support a link between LRRK2 signaling, lysosomal iron dysregulation and ferroptosis-related stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.